PATENT CLAIM ANALYSIS

Application Number: 15913202
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "301000"]

Abstract:
The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.

Claim (Index 18):
The kit of  claim 16 , wherein the other anti-hepatitis C drug comprise peginterferon, ribavirin, daclatasvir, boceprevir, telapravir, simeprevir, sofosbuvir, dasabuvir, ombitasvir, velpatasvir, ledipasvir, paritaprevir, ritonavir, elbasvir, grazoprevir, asunaprevir, beclabuvir, or a combination thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.48148
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15212703', '15364825', '15684192', '15370275', '14538736']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7704615312061346
- 35 USC 102 Novelty (BERT): 0.5601074271689703
- Combined Prediction Score: 0.7494261208024181
- Mean Citation Score: 341.6166540000001
- Max Citation Score: 449.9452
- Similarity Product: 337.4069251194477

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test